
    
      Primary Objective:

        -  To investigate the risk factors of OAB symptom relapse and retreatment in patients who
           showed therapeutic benefits after 1, 3 or 6 months of treatment with Tolterodine SR and
           who then discontinued these antimuscarinics for 3 month.

      Secondary Objective:

        -  To investigate the change of the patient perception and quality of life after
           antimuscarinic discontinuation

        -  To find the rate of patients who have OAB symptom relapse.

        -  To find the risk factors of patients who want retreatment.

        -  To find the rate of patients who want retreatment.
    
  